Capsida Biotherapeutics has entered into a licensing agreement with AbbVie, securing a $40 million upfront payment and potential future milestones to advance their first neurodegenerative disease program utilizing engineered AAV technology.

Information on the Target

Capsida Biotherapeutics is a leading gene therapy company focused on developing innovative treatments for central nervous system (CNS) diseases. With a robust pipeline comprising both rare and common disorders, Capsida aims to address critical therapeutic needs through its advanced gene therapy platforms. Their current programs include ground-breaking treatments for various conditions such as STXBP1 developmental and epileptic encephalopathy, Parkinson’s disease related to GBA mutations, and Friedreich’s ataxia.

Founded in 2019, Capsida emerged from cutting-edge research led by neuroscience professor Viviana Gradinaru at Caltech. The company has established strong partnerships with significant industry players, including AbbVie, Lilly, and CRISPR Therapeutics, enhancing its capacity for innovation and market delivery.

Industry Overview in the Target’s Specific Country

The biotechnology sector in the United States is one of the most advanced and competitive in the world. The country is home to numerous leading biotech firms that are at the forefront of developing cutting-edge therapies, particularl